Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
26S proteasome non-ATPase regulatory subunit 3 (PSMD3) mRNA is the transcript encoding a critical component of the 19S regulatory particle of the 26S proteasome [UniProt KB: O43242]. This subunit is essential for the recognition, unfolding, and translocation of ubiquitinated proteins into the 20S catalytic core for degradation, thereby maintaining cellular protein homeostasis [NCBI Gene: 5709]. PSMD3 is frequently overexpressed in various malignancies, particularly in HER2-positive breast cancer, where it is located on the 17q12-21 amplicon and serves as a key driver of cell proliferation and survival [PMID: 28652445]. Targeting the PSMD3 mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) has been shown in preclinical models to induce proteotoxic stress and apoptosis by depleting the PSMD3 protein and disrupting proteasome assembly [PMID: 31110218]. Beyond oncology, genetic variants in the PSMD3 locus have been associated with metabolic traits, including obesity and type 2 diabetes, suggesting a broader role in systemic metabolism [PMID: 25607358]. While no PSMD3 mRNA-targeted therapies are currently FDA-approved, the transcript remains a significant target for the development of precision RNA-based therapeutics.
Targeted degradation of PSMD3 mRNA via RNA interference (RNAi) or antisense mechanisms, resulting in the depletion of the PSMD3 protein and subsequent inhibition of 26S proteasome assembly and function.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 3 (PSMD3) mRNA (PSMD3 mRNA).